Vivienne Hau
Ophthalmology · Riverside, CANPI 1588850713
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Alcon Research LLC at 46.7% of the total. Reporting peaked in 2021 at $7,370 and has fallen 85.2% since, to $1,092 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $161.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$7K
- Regeneron$2K
- Novartis$1K
- Genentech USA, Inc.$1K
- Apellis Pharmaceuticals, Inc.$788
- Astellas Pharma US Inc$589
- plus $2K from 12 others
Across 286 payments — averaging $3864.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$523K
- Regeneron$427K
- Novartis$88K
- AbbVie$37K
- Bayer$31K
What the payments were for
- Consulting fees$7,00047%
- Travel & lodging$1,74912%
- Food & beverage$6,04540%
- Education$2302%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 2 | $7,030 |
| Regeneron | 15 | $1,873 |
| Novartis | 13 | $1,240 |
| Genentech USA, Inc. | 11 | $1,159 |
| Apellis Pharmaceuticals, Inc. | 10 | $788 |
| Astellas Pharma US Inc | 7 | $589 |
| AbbVie(2 entities) | 9 | $490 |
| Genentech, Inc. | 4 | $338 |
| Bausch & Lomb Americas Inc. | 6 | $327 |
| Regeneron Healthcare Solutions, Inc. | 3 | $316 |
| Dutch Ophthalmic, USA | 2 | $275 |
| Alcon | 3 | $232 |
| Topcon Healthcare, Inc. | 2 | $169 |
| Carl Zeiss Meditec, Inc. | 2 | $75 |
| Neurotech Pharmaceuticals, Inc. | 1 | $51 |
| Alimera Sciences, Inc. | 1 | $42 |
| Astellas Pharma Global Development | 1 | $41 |
| Travere Therapeutics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$916
- BEOVU$782
- SUSVIMO$370
- EYLEA$258
- Syfovre$211
- EVA Ophthalmic Surgical System$183
- MIEBO$149
- XIIDRA$149
- VYZULTA$149
- enVista MX60 IOL$149
- STELLARIS ELITE$149
- Izervay$147
- BUPARLISIB$122
How this compares
$15,042 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 95 | $3,157 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 51 | $1,199 |
| Ketorolac Tromethamine | 43 | $802 |
| Latanoprost | 86 | $705 |
| Ofloxacin | 39 | $568 |
| Brimonidine Tartrate | 22 | $342 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Riverside
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.